Výsledky vyhledávání

Controlled randomized study comparing the cardiovascular profile of everolimus with tacrolimus in renal transplantation

Autor: Joan M. Diaz, Ana Sánchez-Fructuoso, Alexandra Paravisini, Josep M. Cruzado, Manuel Rengel, Daniel Serón, Nuria Saval, Domingo Hernández, José M. Morales, Federico Oppenheimer, Julio Pascual

Publikováno v: TRANSPLANT INTERNATIONAL
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

Left ventricular hypertrophy (LVH) regression after kidney transplantation may be influenced by immunosuppression. In a 24-month open-label, multicenter, phase-IV study, 71 kidney allograft recipients without previous acute rejection, showing eGFR >

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::238f1ec39dc4b837c1452838444baf70
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6841

Zobrazit plný text záznamu

Acute Renal Failure Secondary to Imatinib Mesylate Treatment in Chronic Myeloid Leukemia

Autor: Manel Vera, Anna Saurina, Albert Botey, Francisco Cervantes, Manel Solé, Mónica Pou, Nuria Saval

Publikováno v: Leukemia & Lymphoma. 44:1239-1241

A 58-year-old woman with chronic myeloid leukemia (CML), and previous intolerance to interferon was treated with the BCR-ABL tyrosine kinase protein inhibitor imatinib mesylate. Coincidentally, with the start of treatment, the patient developed acute

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::862e90ddb632b6b4da465a15ec92dc71
https://doi.org/10.1080/1042819031000079140

Zobrazit plný text záznamu

De novo use of everolimus with elimination or minimization of cyclosporine in renal transplant recipients

Autor: A.B. Otero, G. Aldana, Nuria Saval, P. Errasti, Josep M. Grinyó, F.J.P. Ramos, Antonio Franco, J. Pefaur, Federico Oppenheimer, A.M. Marti-Cuadros, P. Novoa

Publikováno v: Transplantation proceedings. 43(9)

Background The purpose of two similarly designed multicenter, prospective, parallel-group, open-label studies was to evaluate early cyclosporine (CsA) elimination versus minimization from an everolimus-CsA-steroid regimen in de novo renal transplant

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c09573c75d67f5aa2aa49bcbd1d09a81
https://pubmed.ncbi.nlm.nih.gov/22099791

Zobrazit plný text záznamu